Can Historical Balance Sheet

CANF Stock

USD 1.57 0.05 3.09%

Trend analysis of Can Fite Biopharma balance sheet accounts such as Total Assets of 10.5 M, Other Current Liabilities of 891.4 K or Total Current Liabilities of 2.4 M provides information on Can Fite's total assets, liabilities, and equity, which is the actual value of Can Fite Biopharma to its prevalent stockholders. By breaking down trends over time using Can Fite balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Can Fite Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Can Fite Biopharma is a good buy for the upcoming year.

Can Fite Inventory

(47,092.5)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Can Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Can Fite Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Can Fite Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Can Fite and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Can currently owns. An asset can also be divided into two categories, current and non-current.

Can Fite Balance Sheet Chart

At this time, Can Fite's Other Assets are most likely to increase significantly in the upcoming years. The Can Fite's current Common Stock Total Equity is estimated to increase to about 39.9 M, while Total Assets are projected to decrease to roughly 10.5 M.

Common Stock Shares Outstanding Total Assets Other Current Liab Total Current Liabilities

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Can Fite assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Can Fite Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Can Fite balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Can Fite Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Can Fite's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Can Fite Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	727K	944K	1.1M	891.4K
Total Assets	9.3M	10.0M	11.5M	10.5M

Other Current Liab Total Assets

Can Fite balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Treasury Stock	Common Stock	Property Plant Equipment	Net Tangible Assets
Common Stock Shares Outstanding		0.36	-0.1	0.14	0.38	0.25	0.71	0.12	-0.48	-0.1	-0.1	-0.08	0.44	0.38	-0.23	0.5	0.19	-0.11	0.27	0.21	0.01	0.36	0.27	0.47	0.57	-0.09
Total Assets	0.36		0.19	0.17	0.96	0.84	0.53	-0.55	-0.47	-0.33	0.54	-0.05	0.37	0.95	-0.21	0.42	0.78	0.0	0.29	0.73	0.29	1.0	0.57	0.44	0.53	0.01
Other Current Liab	-0.1	0.19		0.34	0.06	0.32	-0.22	-0.07	-0.16	-0.51	0.05	-0.02	-0.02	0.15	0.05	0.03	0.36	0.25	0.23	0.44	0.12	0.19	0.15	0.1	-0.12	-0.01
Total Current Liabilities	0.14	0.17	0.34		-0.01	0.18	0.26	0.36	-0.37	0.32	-0.36	0.28	0.31	-0.01	0.15	0.15	0.2	0.64	0.28	0.54	0.17	0.15	0.27	0.22	0.23	-0.48
Total Stockholder Equity	0.38	0.96	0.06	-0.01		0.74	0.57	-0.51	-0.45	-0.39	0.5	-0.18	0.39	0.97	-0.28	0.48	0.59	-0.2	0.27	0.51	0.33	0.97	0.48	0.49	0.59	0.16
Other Liab	0.25	0.84	0.32	0.18	0.74		0.4	-0.63	-0.45	-0.43	0.61	0.01	0.4	0.77	-0.17	0.38	0.81	0.09	0.41	0.76	0.29	0.83	0.52	0.37	0.48	-0.19
Property Plant And Equipment Net	0.71	0.53	-0.22	0.26	0.57	0.4		0.18	-0.62	-0.04	-0.18	0.14	0.77	0.49	-0.36	0.69	0.23	-0.04	0.33	0.29	0.39	0.52	0.14	0.65	0.92	-0.23
Net Debt	0.12	-0.55	-0.07	0.36	-0.51	-0.63	0.18		-0.17	0.34	-1.0	0.27	0.22	-0.6	0.18	0.14	-0.64	0.23	0.12	-0.42	0.15	-0.57	-0.39	0.18	0.16	-0.24
Retained Earnings	-0.48	-0.47	-0.16	-0.37	-0.45	-0.45	-0.62	-0.17		0.33	0.19	-0.09	-0.89	-0.4	0.22	-0.92	-0.33	-0.23	-0.83	-0.42	-0.77	-0.46	-0.44	-0.91	-0.71	0.54
Accounts Payable	-0.1	-0.33	-0.51	0.32	-0.39	-0.43	-0.04	0.34	0.33		-0.31	0.54	-0.26	-0.45	0.32	-0.48	-0.23	0.36	-0.33	-0.08	-0.46	-0.36	0.01	-0.48	-0.2	-0.18
Cash	-0.1	0.54	0.05	-0.36	0.5	0.61	-0.18	-1.0	0.19	-0.31		-0.26	-0.25	0.59	-0.17	-0.17	0.64	-0.23	-0.16	0.41	-0.2	0.56	0.4	-0.22	-0.18	0.26
Non Current Assets Total	-0.08	-0.05	-0.02	0.28	-0.18	0.01	0.14	0.27	-0.09	0.54	-0.26		0.12	-0.29	0.36	-0.13	0.22	0.66	0.05	0.29	-0.11	-0.12	0.23	-0.16	0.02	-0.37
Other Assets	0.44	0.37	-0.02	0.31	0.39	0.4	0.77	0.22	-0.89	-0.26	-0.25	0.12		0.32	-0.45	0.93	0.17	0.08	0.71	0.26	0.8	0.36	0.22	0.89	0.85	-0.44
Cash And Short Term Investments	0.38	0.95	0.15	-0.01	0.97	0.77	0.49	-0.6	-0.4	-0.45	0.59	-0.29	0.32		-0.38	0.44	0.65	-0.29	0.25	0.56	0.3	0.97	0.44	0.46	0.52	0.18
Net Receivables	-0.23	-0.21	0.05	0.15	-0.28	-0.17	-0.36	0.18	0.22	0.32	-0.17	0.36	-0.45	-0.38		-0.43	0.0	0.64	-0.18	0.05	-0.36	-0.23	0.08	-0.42	-0.43	-0.28
Common Stock Total Equity	0.5	0.42	0.03	0.15	0.48	0.38	0.69	0.14	-0.92	-0.48	-0.17	-0.13	0.93	0.44	-0.43		0.17	-0.08	0.73	0.2	0.84	0.43	0.19	0.97	0.8	-0.36
Non Current Liabilities Total	0.19	0.78	0.36	0.2	0.59	0.81	0.23	-0.64	-0.33	-0.23	0.64	0.22	0.17	0.65	0.0	0.17		0.32	0.24	0.93	0.08	0.76	0.6	0.15	0.17	-0.27
Other Current Assets	-0.11	0.0	0.25	0.64	-0.2	0.09	-0.04	0.23	-0.23	0.36	-0.23	0.66	0.08	-0.29	0.64	-0.08	0.32		0.17	0.51	-0.05	-0.05	0.46	-0.1	-0.13	-0.6
Other Stockholder Equity	0.27	0.29	0.23	0.28	0.27	0.41	0.33	0.12	-0.83	-0.33	-0.16	0.05	0.71	0.25	-0.18	0.73	0.24	0.17		0.31	0.72	0.29	0.38	0.76	0.57	-0.57
Total Liab	0.21	0.73	0.44	0.54	0.51	0.76	0.29	-0.42	-0.42	-0.08	0.41	0.29	0.26	0.56	0.05	0.2	0.93	0.51	0.31		0.13	0.71	0.62	0.21	0.23	-0.41
Property Plant And Equipment Gross	0.01	0.29	0.12	0.17	0.33	0.29	0.39	0.15	-0.77	-0.46	-0.2	-0.11	0.8	0.3	-0.36	0.84	0.08	-0.05	0.72	0.13		0.29	-0.01	0.88	0.61	-0.36
Total Current Assets	0.36	1.0	0.19	0.15	0.97	0.83	0.52	-0.57	-0.46	-0.36	0.56	-0.12	0.36	0.97	-0.23	0.43	0.76	-0.05	0.29	0.71	0.29		0.55	0.44	0.52	0.04
Treasury Stock	0.27	0.57	0.15	0.27	0.48	0.52	0.14	-0.39	-0.44	0.01	0.4	0.23	0.22	0.44	0.08	0.19	0.6	0.46	0.38	0.62	-0.01	0.55		0.15	0.12	-0.16
Common Stock	0.47	0.44	0.1	0.22	0.49	0.37	0.65	0.18	-0.91	-0.48	-0.22	-0.16	0.89	0.46	-0.42	0.97	0.15	-0.1	0.76	0.21	0.88	0.44	0.15		0.77	-0.32
Property Plant Equipment	0.57	0.53	-0.12	0.23	0.59	0.48	0.92	0.16	-0.71	-0.2	-0.18	0.02	0.85	0.52	-0.43	0.8	0.17	-0.13	0.57	0.23	0.61	0.52	0.12	0.77		-0.28
Net Tangible Assets	-0.09	0.01	-0.01	-0.48	0.16	-0.19	-0.23	-0.24	0.54	-0.18	0.26	-0.37	-0.44	0.18	-0.28	-0.36	-0.27	-0.6	-0.57	-0.41	-0.36	0.04	-0.16	-0.32	-0.28

Click cells to compare fundamentals

Can Fite Account Relationship Matchups

Can Fite balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Common Stock Shares Outstanding	358.4M	553.1M	815.7M	4.3M	4.9M	4.7M
Total Assets	9.5M	20.3M	9.3M	10.0M	11.5M	10.5M
Other Current Liab	288K	852K	727K	944K	1.1M	891.4K
Total Current Liabilities	1.3M	2.7M	2.5M	2.0M	2.3M	2.4M
Total Stockholder Equity	6.1M	14.4M	4.5M	6.2M	7.2M	5.6M
Other Liab	2.4M	2.2M	3.1M	2.3M	2.6M	2.0M
Property Plant And Equipment Net	123K	185K	126K	81K	93.2K	87.2K
Net Debt	(8.2M)	(4.3M)	(2.9M)	(4.2M)	(4.9M)	(5.1M)
Retained Earnings	(125.5M)	(140.7M)	(150.8M)	(158.5M)	(142.6M)	(149.8M)
Accounts Payable	561K	954K	896K	427K	384.3K	365.1K
Cash	8.3M	4.4M	3.0M	4.3M	3.9M	4.6M
Non Current Assets Total	123K	185K	126K	81K	93.2K	88.5K
Cash And Short Term Investments	8.3M	19.1M	8.0M	8.9M	10.3M	8.4M
Net Receivables	18K	48K	47K	78K	70.2K	66.7K
Liabilities And Stockholders Equity	9.5M	20.3M	9.3M	10.0M	11.5M	10.5M
Non Current Liabilities Total	2.2M	3.1M	2.3M	1.7M	2.0M	2.4M
Other Current Assets	1.0M	881K	1.1M	986K	1.1M	1.6M
Other Stockholder Equity	97.4M	93.3M	154.2M	163.6M	188.1M	106.5M
Total Liab	3.4M	5.9M	4.8M	3.7M	4.3M	4.8M
Property Plant And Equipment Gross	123K	185K	126K	344K	395.6K	415.4K
Total Current Assets	9.4M	20.1M	9.2M	9.9M	11.4M	10.3M
Common Stock	2.6M	8.2M	33.0M	60.7M	69.8M	73.2M
Property Plant Equipment	118K	123K	185K	126K	144.9K	84.8K
Net Tangible Assets	2.4M	6.1M	14.4M	4.5M	4.0M	7.2M
Non Currrent Assets Other	912K	(123K)	(185K)	(126K)	(113.4K)	(107.7K)
Current Deferred Revenue	334K	818K	783K	622K	715.3K	594.8K
Short Term Debt	86K	106K	96K	27K	24.3K	23.1K
Net Invested Capital	6.1M	14.4M	4.5M	6.2M	7.2M	6.0M
Net Working Capital	8.1M	17.3M	6.7M	7.9M	9.1M	8.4M
Short Term Investments	75K	14.7M	5.0M	4.6M	5.3M	4.5M
Short Long Term Debt Total	67K	124K	62K	40K	36K	58.9K
Capital Lease Obligations	67K	124K	62K	40K	36K	58.9K

Currently Active Assets on Macroaxis

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria
HMY	Harmony Gold Mining
FSM	Fortuna Silver Mines

When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:

How To Invest In Can

Details

Is Can Stock a good investment?

Details

What is Can Fite's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.60)

Quarterly Revenue Growth

(0.19)

Return On Assets

(0.57)

Return On Equity

(1.58)

The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Can Historical Balance Sheet

Can Fite Inventory

(47,092.5)

About Can Balance Sheet Analysis

Can Fite Balance Sheet Chart

Common Stock Shares Outstanding

Total Assets

Total Current Liabilities

Can Fite balance sheet Correlations

Can Fite Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Can Fite balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 0.97	Total Stockholder Equity
Total Current Assets	+ 0.97	Total Stockholder Equity
Total Current Assets	+ 0.97	Cash And Short Term Investments
Common Stock	+ 0.97	Common Stock Total Equity
Total Stockholder Equity	+ 0.96	Total Assets

Cash	- 1.0	Net Debt
Common Stock Total Equity	- 0.92	Retained Earnings
Common Stock	- 0.91	Retained Earnings
Other Assets	- 0.89	Retained Earnings
Other Stockholder Equity	- 0.83	Retained Earnings
Property Plant And Equipment Gross	- 0.77	Retained Earnings